Status:
UNKNOWN
Clinical Study of Imaging Genomics Based on Machine Learning for BCIG
Lead Sponsor:
Fudan University
Collaborating Sponsors:
RenJi Hospital
International Peace Maternity and Child Health Hospital
Conditions:
Breast Cancer
Molecular Typing
Eligibility:
FEMALE
Brief Summary
1. Identify the imaging features of breast cancer with different molecular types 2. Reveal the association between hormone receptor positive/HER2 negative breast cancer and imaging histology, Oncotype...
Detailed Description
Research design 1. Research on the molecular typing of breast cancer based on imaging features 2. Establish a Luminal breast cancer recurrence risk prediction model 3. Establish HER2 targeted therapy...
Eligibility Criteria
Inclusion
- Pathological and immunohistochemical diagnosis of breast cancer by biopsy
- No MRI contraindications and no biopsy before MRI
- Without radiotherapy and chemotherapy before enrollment
Exclusion
- Those with previous history of breast cancer surgery, hormone replacement therapy and chest radiotherapy
- Patients with severe diseases who cannot cooperate with the examination
- People with contraindications to MRI
- The researchers believe that other conditions are not suitable for breast MRI examination
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2023
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04461990
Start Date
December 1 2020
End Date
December 30 2023
Last Update
August 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032